A phase II trial of imatinib mesylate (Gleevec®) in myeloproliferative disorders other than CML.

被引：0
作者：
Kuriakose, P
Shurafa, MS
机构：
[1] Henry Ford Hosp, Div Hematol Oncol, Detroit, MI 48202 USA
[2] Van Elslander Canc Ctr, Grosse Pointe Woods, MI USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4765
引用
收藏
页码：274B / 274B
页数：1
相关论文
共 50 条
  • [21] The emergence of cytogenetically unrelated clones may not be an uncommon finding in imatinib mesylate-treated CML.
    Sun, GX
    Boczkowska, B
    Tcheurekdjian, L
    Lorenzo, M
    Owens, M
    [J]. BLOOD, 2002, 100 (11) : 326B - 326B
  • [22] Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma
    Vuky, J
    Isacson, C
    Fotoohi, M
    dela Cruz, J
    Otero, H
    Picozzi, V
    Malpass, T
    Aboulafia, D
    Jacobs, A
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (01) : 85 - 88
  • [23] Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma
    Jacqueline Vuky
    Christina Isacson
    Mehran Fotoohi
    Jason dela Cruz
    Henry Otero
    Vincent Picozzi
    Thomas Malpass
    David Aboulafia
    Andrew Jacobs
    [J]. Investigational New Drugs, 2006, 24 : 85 - 88
  • [24] Gleevec™(imatinib mesylate) induced hematologic and cytogenetic responses confirmed and expanded in patient's with chronic myeloid leukemia (CML) -: A phase II study update.
    Kantarjian, HM
    Sawyers, CL
    Hochhaus, A
    Guilhot, F
    Schiffer, CA
    Deininger, MW
    Gambacorti-Passerini, C
    Stone, RM
    Goldman, J
    Fischer, T
    Rosamilia, M
    Zoellner, U
    Resta, D
    Capdeville, R
    Druker, BJ
    [J]. BLOOD, 2001, 98 (11) : 845A - 845A
  • [25] Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML.
    Seymour, John Francis
    Grigg, Andrew
    Reynolds, John
    Schwarer, Anthony P.
    Hermann, Richard
    Taylor, Kern McDonald
    Bradstock, Kenneth Francis
    Mills, Anthony K.
    Koelmeyer, Rachel
    Lynch, Kevin
    Hughes, Timothy
    [J]. BLOOD, 2006, 108 (11) : 609A - 609A
  • [26] A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer
    Gharibo, Mecide
    Patrick-Miller, Linda
    Zheng, Ling
    Guensch, Lisa
    Juvidian, Parisa
    Poplin, Elizabeth
    [J]. PANCREAS, 2008, 36 (04) : 341 - 345
  • [27] Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders
    Apostolia M. Tsimberidou
    Dawn E. Colburn
    Mary Alma Welch
    Jorge E. Cortes
    Srdan Verstovsek
    Susan M. O'Brien
    Maher Albitar
    Hagop M. Kantarjian
    Francis J. Giles
    [J]. Cancer Chemotherapy and Pharmacology, 2003, 52 : 229 - 234
  • [28] Imatinib mesylate in chronic idiopathic myelofibrosis, a phase II trial.
    Gisslinger, H
    Gisslinger, B
    Kees, M
    Maurer, U
    Schoder, R
    Grumbeck, E
    Thiele, J
    Lechner, K
    Simonitsch-Klupp, I
    [J]. BLOOD, 2002, 100 (11) : 800A - 801A
  • [29] Imatinib mesylate in the treatment of systemic mastocytosis, a phase I/II trial
    Droogendijk, HJ
    Kluin-Nelemans, JC
    van Daele, PLA
    [J]. BLOOD, 2004, 104 (11) : 424A - 424A
  • [30] Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial
    Mathy, A
    Baas, P
    Dalesio, O
    van Zandwijk, N
    [J]. LUNG CANCER, 2005, 50 (01) : 83 - 86
12345